AR060845A1 - Compuestos restringidos como antagonistas del receptor cgrp - Google Patents
Compuestos restringidos como antagonistas del receptor cgrpInfo
- Publication number
- AR060845A1 AR060845A1 ARP070101906A ARP070101906A AR060845A1 AR 060845 A1 AR060845 A1 AR 060845A1 AR P070101906 A ARP070101906 A AR P070101906A AR P070101906 A ARP070101906 A AR P070101906A AR 060845 A1 AR060845 A1 AR 060845A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- halo
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000001475 halogen functional group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- -1 N- (R9) -piperazinyl Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010003497 Asphyxia Diseases 0.000 abstract 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Chemical group 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000006357 methylene carbonyl group Chemical group [H]C([H])([*:1])C([*:2])=O 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79740006P | 2006-05-03 | 2006-05-03 | |
| US11/742,626 US7470680B2 (en) | 2006-05-03 | 2007-05-01 | Constrained compounds as CGRP-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060845A1 true AR060845A1 (es) | 2008-07-16 |
Family
ID=38544174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101906A AR060845A1 (es) | 2006-05-03 | 2007-05-02 | Compuestos restringidos como antagonistas del receptor cgrp |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7470680B2 (https=) |
| EP (1) | EP2013214B1 (https=) |
| JP (1) | JP2009535429A (https=) |
| KR (1) | KR20090018930A (https=) |
| AR (1) | AR060845A1 (https=) |
| AU (1) | AU2007248038A1 (https=) |
| BR (1) | BRPI0709759A2 (https=) |
| CA (1) | CA2651033A1 (https=) |
| IL (1) | IL195027A0 (https=) |
| MX (1) | MX2008013760A (https=) |
| NO (1) | NO20084564L (https=) |
| PE (1) | PE20080232A1 (https=) |
| TW (1) | TW200813063A (https=) |
| WO (1) | WO2007131020A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| EP2120564A4 (en) * | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2024220626A1 (en) * | 2023-04-20 | 2024-10-24 | Azkarra Therapeutics, Inc. | Small molecule modulators of ogg1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| JP4705908B2 (ja) * | 2003-04-15 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| WO2005000807A2 (en) | 2003-06-26 | 2005-01-06 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| JP4705922B2 (ja) | 2004-01-29 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2582593A1 (en) | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| AU2005295855B2 (en) | 2004-10-14 | 2011-08-18 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| AU2005299852B2 (en) | 2004-10-22 | 2011-08-04 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| CA2594940A1 (en) | 2005-01-18 | 2006-07-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| CN101208303A (zh) | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
| WO2007016087A2 (en) | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| EP2120564A4 (en) | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
-
2007
- 2007-05-01 US US11/742,626 patent/US7470680B2/en active Active
- 2007-05-02 EP EP07761726.4A patent/EP2013214B1/en active Active
- 2007-05-02 KR KR1020087029499A patent/KR20090018930A/ko not_active Withdrawn
- 2007-05-02 MX MX2008013760A patent/MX2008013760A/es not_active Application Discontinuation
- 2007-05-02 JP JP2009510047A patent/JP2009535429A/ja active Pending
- 2007-05-02 AR ARP070101906A patent/AR060845A1/es not_active Application Discontinuation
- 2007-05-02 WO PCT/US2007/067998 patent/WO2007131020A2/en not_active Ceased
- 2007-05-02 AU AU2007248038A patent/AU2007248038A1/en not_active Abandoned
- 2007-05-02 PE PE2007000536A patent/PE20080232A1/es not_active Application Discontinuation
- 2007-05-02 CA CA002651033A patent/CA2651033A1/en not_active Abandoned
- 2007-05-02 BR BRPI0709759-0A patent/BRPI0709759A2/pt not_active IP Right Cessation
- 2007-05-03 TW TW096115732A patent/TW200813063A/zh unknown
-
2008
- 2008-10-30 IL IL195027A patent/IL195027A0/en unknown
- 2008-10-30 NO NO20084564A patent/NO20084564L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090018930A (ko) | 2009-02-24 |
| WO2007131020A2 (en) | 2007-11-15 |
| US7470680B2 (en) | 2008-12-30 |
| CA2651033A1 (en) | 2007-11-15 |
| EP2013214A2 (en) | 2009-01-14 |
| JP2009535429A (ja) | 2009-10-01 |
| TW200813063A (en) | 2008-03-16 |
| MX2008013760A (es) | 2008-11-14 |
| AU2007248038A1 (en) | 2007-11-15 |
| WO2007131020A3 (en) | 2008-01-17 |
| BRPI0709759A2 (pt) | 2011-10-25 |
| US20070259851A1 (en) | 2007-11-08 |
| PE20080232A1 (es) | 2008-04-11 |
| IL195027A0 (en) | 2009-08-03 |
| NO20084564L (no) | 2008-12-02 |
| EP2013214B1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071314A1 (es) | Antagonistas de receptor de cgrp | |
| AR078638A1 (es) | Antagonistas del receptor de cgrp | |
| AR051755A1 (es) | Compuestos biciclicos y triciclicos antagonistas del receptor cgrp | |
| AR060845A1 (es) | Compuestos restringidos como antagonistas del receptor cgrp | |
| CY1122121T1 (el) | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας | |
| AR082986A1 (es) | DERIVADOS DE PURINA COMO INHIBIDORES DE PI3K-d, METODOS PARA SU PREPARACION, FORMULACIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS | |
| ECSP078018A (es) | Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| EA201170520A1 (ru) | Ингибитор p38 mapk-киназы | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| AR076271A1 (es) | Inhibidores de mtor, composiciones farmaceuticas, metodo de fabricacion y su uso en el tratamiento de cancer | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| ECSP13012416A (es) | Derivados heterocíclicos fusionados como moduladores s1p | |
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| AR123543A1 (es) | DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5 | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |